Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 30
- Registration Number
- NCT05142865
- Locations
- 🇨🇳
Tongji Hospital，Tongji Medical College Affiliated，Huazhong University of Science ＆ Technology, Wuhan, Hubei, China
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
- Conditions
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05137262
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
- Conditions
- Interventions
- First Posted Date
- 2021-11-29
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT05136677
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou Universtiy-Oncology department, Zhengzhou, Henan, China
🇨🇳Local Institution - 0012, Ningbo, Zhejiang, China
🇨🇳Beijing Cancer hospital-Thoracic Cancer Department A, Beijing, Beijing, China
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 45
- Registration Number
- NCT05132985
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 80
- Registration Number
- NCT05125055
- Locations
- 🇨🇳
Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Phase II Study of Neoadjuvant Sotorasib in Combination with Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer with a KRAS P.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2021-11-12
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT05118854
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT05116462
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 27
- Registration Number
- NCT05104788
- Locations
- 🇨🇳
BeijingCancerH, Beijing, China
A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2021-12-28
- Target Recruit Count
- 20
- Registration Number
- NCT05105672
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 157
- Registration Number
- NCT05076942
- Locations
- 🇺🇸
Duke Women's Cancer Care Raleigh, Raleigh, North Carolina, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Nassau, Uniondale, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.